Compare Stocks: OKUR, KYTX, IRD, and ZURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRD Opus Genetics	$4.27 +0.7%	$4.49	$1.70 ▼ $7.07	$353.33M	0.62	1.42 million shs	392,027 shs
KYTX Kyverna Therapeutics	$5.71 -1.0%	$7.54	$5.63 ▼ $13.67	$353.97M	2.06	916,638 shs	353,667 shs
OKUR OnKure Therapeutics	$2.34 -0.6%	$3.32	$2.13 ▼ $5.38	$94.25M	0.12	261,047 shs	40,079 shs
ZURA Zura Bio	$4.51 +6.6%	$5.13	$3.15 ▼ $7.44	$430.76M	0.01	1.18 million shs	2.24 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRD Opus Genetics	-8.62%	-3.20%	-29.80%	+21.84%	+112.00%
KYTX Kyverna Therapeutics	-7.09%	-6.33%	-20.52%	-25.84%	-16.74%
OKUR OnKure Therapeutics	-2.89%	-4.47%	-24.19%	-44.18%	-18.40%
ZURA Zura Bio	+5.75%	+6.82%	-18.81%	-21.52%	+9.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRD Opus Genetics	$4.27 +0.7%	$4.49	$1.70 ▼ $7.07	$353.33M	0.62	1.42 million shs	392,027 shs
KYTX Kyverna Therapeutics	$5.71 -1.0%	$7.54	$5.63 ▼ $13.67	$353.97M	2.06	916,638 shs	353,667 shs
OKUR OnKure Therapeutics	$2.34 -0.6%	$3.32	$2.13 ▼ $5.38	$94.25M	0.12	261,047 shs	40,079 shs
ZURA Zura Bio	$4.51 +6.6%	$5.13	$3.15 ▼ $7.44	$430.76M	0.01	1.18 million shs	2.24 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRD Opus Genetics	-8.62%	-3.20%	-29.80%	+21.84%	+112.00%
KYTX Kyverna Therapeutics	-7.09%	-6.33%	-20.52%	-25.84%	-16.74%
OKUR OnKure Therapeutics	-2.89%	-4.47%	-24.19%	-44.18%	-18.40%
ZURA Zura Bio	+5.75%	+6.82%	-18.81%	-21.52%	+9.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRD Opus Genetics	2.89	Moderate Buy	$12.29	187.65% Upside
KYTX Kyverna Therapeutics	2.86	Moderate Buy	$29.00	407.53% Upside
OKUR OnKure Therapeutics	2.25	Hold	$17.50	649.46% Upside
ZURA Zura Bio	2.86	Moderate Buy	$17.00	276.86% Upside

Current Analyst Ratings Breakdown

Latest OKUR, KYTX, IRD, and ZURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	OKUR OnKure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/6/2026	IRD Opus Genetics	JonesTrading Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$10.00 ➝ $17.00
10/2/2026	ZURA Zura Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/2/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$16.00
9/25/2026	KYTX Kyverna Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$25.00
9/25/2026	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/25/2026	KYTX Kyverna Therapeutics	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/23/2026	KYTX Kyverna Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/21/2026	KYTX Kyverna Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/21/2026	OKUR OnKure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/10/2026	IRD Opus Genetics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$10.00 ➝ $13.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRD Opus Genetics	$14.20M	24.86	N/A	N/A	$0.22 per share	19.41
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$3.85 per share	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRD Opus Genetics	-$49.59M	-$1.35	N/A	N/A	N/A	-1,091.82%	N/A	-150.13%	11/11/2026 (Estimated)
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	11/11/2026 (Estimated)
OKUR OnKure Therapeutics	-$59.52M	-$3.50	N/A	N/A	N/A	N/A	-49.01%	-45.77%	11/5/2026 (Estimated)
ZURA Zura Bio	-$99.35M	-$1.13	N/A	N/A	N/A	N/A	-56.13%	-50.15%	11/12/2026 (Estimated)

Latest OKUR, KYTX, IRD, and ZURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	IRD Opus Genetics	-$0.14	N/A	N/A	N/A	$1.54 million	N/A
11/11/2026	Q3 2026	KYTX Kyverna Therapeutics	-$0.68	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	OKUR OnKure Therapeutics	-$0.36	N/A	N/A	N/A	$0.17 million	N/A
8/11/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/11/2026	Q2 2026	ZURA Zura Bio	-$0.1913	-$0.21	-$0.0187	-$0.21	N/A	N/A
8/6/2026	Q2 2026	IRD Opus Genetics	-$0.1567	-$0.14	+$0.0167	-$0.14	$2.63 million	$0.76 million
8/4/2026	Q2 2026	OKUR OnKure Therapeutics	-$0.5350	-$0.31	+$0.2250	-$0.31	$0.17 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRD Opus Genetics	N/A	12.19	12.19
KYTX Kyverna Therapeutics	0.15	9.06	9.06
OKUR OnKure Therapeutics	N/A	26.75	26.75
ZURA Zura Bio	N/A	12.90	12.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRD Opus Genetics	14.97%
KYTX Kyverna Therapeutics	18.08%
OKUR OnKure Therapeutics	90.98%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
IRD Opus Genetics	11.70%
KYTX Kyverna Therapeutics	17.60%
OKUR OnKure Therapeutics	2.17%
ZURA Zura Bio	12.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRD Opus Genetics	28	82.65 million	72.98 million	N/A
KYTX Kyverna Therapeutics	149	61.84 million	50.96 million	Optionable
OKUR OnKure Therapeutics	45	40.40 million	39.52 million	N/A
ZURA Zura Bio	40	95.83 million	83.98 million	Optionable

OKUR, KYTX, IRD, and ZURA Headlines

Recent News About These Companies

Analysts Are Bullish on These Healthcare Stocks: Zura Bio (ZURA), Alphatec Holdings (ATEC)

October 9, 2026 | theglobeandmail.com

Piper Sandler keeps Buy rating for Zura Bio stock

October 8, 2026 | ad-hoc-news.deA

This biotech stock is a top pick at Guggenheim

October 7, 2026 | finance.yahoo.com

Zura Bio Limited (NASDAQ:ZURA) Stock Has Average Target Price of $17.00

October 6, 2026 | marketbeat.com

Guggenheim reiterates Buy rating for Zura Bio stock

October 5, 2026 | ad-hoc-news.deA

Zura Bio stock heads into Piper Sandler meeting with losses widening

October 4, 2026 | ad-hoc-news.deA

Zura Bio (NASDAQ:ZURA) Shares Down 0.7% - Here's What Happened

October 3, 2026 | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Stock Price Down 0.7% - Here's What Happened

October 3, 2026 | marketbeat.com

Zura Bio stock enters a key trial data phase

September 29, 2026 | ad-hoc-news.deA

Zura Bio stock extends multi-month rally on strong pipeline expectations

September 20, 2026 | ad-hoc-news.deA

Zura Bio Limited Class A Ordinary Shares

September 19, 2026 | livemint.com

Zura Bio Limited (ZURA) Latest Press Releases & Corporate News - Yahoo Finance

September 17, 2026 | finance.yahoo.com

Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply

September 11, 2026 | finance.yahoo.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | businesswire.com

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

August 11, 2026 | businesswire.com

Zura Bio Stock (NASDAQ:ZURAW), Analyst Ratings, Price Targets, Predictions

July 27, 2026 | benzinga.com

William Blair Starts Zura Bio (ZURA) at Outperform

July 14, 2026 | uk.finance.yahoo.com

Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist

July 9, 2026 | businesswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Zura Bio (ZURA)

July 9, 2026 | theglobeandmail.com

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

June 29, 2026 | finance.yahoo.com

Zura Bio (ZURA) Gets a Buy from Oppenheimer

June 13, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OKUR, KYTX, IRD, and ZURA Company Descriptions

Opus Genetics NASDAQ:IRD

$4.27 +0.03 (+0.73%)

As of 11:32 AM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Kyverna Therapeutics NASDAQ:KYTX

$5.71 -0.06 (-0.97%)

As of 11:32 AM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

OnKure Therapeutics NASDAQ:OKUR

$2.34 -0.02 (-0.64%)

As of 11:31 AM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Zura Bio NASDAQ:ZURA

$4.51 +0.28 (+6.64%)

As of 11:32 AM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OKUR, KYTX, IRD, and ZURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OKUR, KYTX, IRD, and ZURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OKUR, KYTX, IRD, and ZURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OKUR, KYTX, IRD, and ZURA Company Descriptions

Opus Genetics NASDAQ:IRD

Kyverna Therapeutics NASDAQ:KYTX

OnKure Therapeutics NASDAQ:OKUR

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OKUR, KYTX, IRD, and ZURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OKUR, KYTX, IRD, and ZURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OKUR, KYTX, IRD, and ZURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OKUR, KYTX, IRD, and ZURA Company Descriptions

Opus Genetics NASDAQ:IRD

Kyverna Therapeutics NASDAQ:KYTX

OnKure Therapeutics NASDAQ:OKUR

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools